CVS Group plc — LSE:CVSG is in focus after a 4.92% decline on 1 October 2026 despite recently reporting a solid full-year performance. CVS reported FY2026Revenueof £712.8m, up 5.9%, with like-for-like sales growth of 2.1%. Australian revenue rose to £79.1m and represented about 11% …
• Arecor Therapeutics is in focus after a busy late-September period that included interim results and a proposed fundraising of up to £5.13 million. The company develops improved formulations of medicines using its Arestat technology platform, with a particular focus on diabetes and cardiometabolic …
• EKF Diagnostics is in focus as the diagnostics specialist showcases its point-of-care and laboratory technologies at EAHS Africa in Nairobi on 1–2 October 2026. The company is presenting products including the DiaSpect Tm and Hemo Control haemoglobin systems and Quo-Lab and Quo-Test HbA1c …
• Fusion Antibodies is in focus as the biotechnology services company continues to develop its pre-clinical antibody discovery, engineering andSupplyactivities. A notable recent development was the grant of a CanadianPatentfor its OptiMAL technology in September 2026. The patent covers antibody-library technology and supports the …
• Renalytix is in focus as the precision-medicine diagnostics company advances commercialisation of KidneyIntelX.dkd, its kidney-disease risk assessment technology. A major recent development was a multi-year agreement with Quest Diagnostics to expand availability of KidneyIntelX.dkd in the United States. The company also completed a …
SkinBioTherapeutics is a Newcastle-based life science company focused on skin health. Its proprietary SkinBiotix platform originates from research at the University of Manchester. The company sells AxisBiotix food supplements targeting the gut-skin axis, aimed at conditions such as psoriasis, acne and eczema. These products …
The 3.85% gain indicates a clear improvement in near-term trading sentiment. In smaller and mid-cap shares, a positive session can be amplified by limited liquidity, fresh corporate information, sector rotation or investors repositioning ahead of expected milestones. For AOTI, Inc. (LSE:AOTI), the latest company …
The 4.35% gain indicates a clear improvement in near-term trading sentiment. In smaller and mid-cap shares, a positive session can be amplified by limited liquidity, fresh corporate information, sector rotation or investors repositioning ahead of expected milestones. For Eden Research plc (LSE:EDEN), the latest …
The 3.77% gain indicates a clear improvement in near-term trading sentiment. In smaller and mid-cap shares, a positive session can be amplified by limited liquidity, fresh corporate information, sector rotation or investors repositioning ahead of expected milestones. For HemoGenyx Pharmaceuticals Plc (LSE:HEMO), the latest …
CRISM Therapeutics Corporation (LSE:CRTX) advanced 5.26% on 1 October 2026, placing the stock among the stronger movers in its part of the UK market. The gain has increased investor attention at a time when small- and mid-cap shares are reacting sharply to fresh corporate …